Pursuant to Regulation 29(1) (e) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Acutaas Chemicals has informed that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, April 30, 2026 to consider the recommendation of Final Dividend for the F.Y. 2025-26 to the equity shareholders of the Company, subject to the approval by members in the ensuing Annual General Meeting. Further pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and in accordance with our intimation letter dated March 25, 2026 Trading Window for dealing in shares of the Company by designated persons, has been closed from April 1, 2026 and shall reopen on May 4, 2026.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1834.40 |
| Dr. Reddys Lab | 1306.80 |
| Cipla | 1362.85 |
| Zydus Lifesciences | 940.10 |
| Lupin | 2459.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: